Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can manifest as mild to severe flu-like and non-flu-like symptoms and signs, which are associated with immune dysfunction and increased mortality. The findings from COVID-19 patients imply a link between immune system abnormalities such as impaired T-cell responses or cytokine imbalances and increased risk for worse clinical outcomes, which has not been fully understood. Owing to the regulatory role of inhibitory immune checkpoints during COVID-19 infection, this review summarizes the available studies concerning the TIM3 as a relatively less characterized immune checkpoint in COVID-19 patients.

Department of Cell Biology Faculty of Science Charles University Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Hu B., et al. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19(3):141–154. PubMed PMC

Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. The Medical journal of Australia. 2020;213(2):54–56.e1. PubMed PMC

Elezkurtaj S., et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci. Rep. 2021;11(1):4263. PubMed PMC

Diao B., et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front. Immunol. 2020;11:827. PubMed PMC

He X., Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. PubMed PMC

Schönrich G., Raftery M.J. The PD-1/PD-L1 Axis and virus infections: a delicate balance. Front. Cell. Infect. Microbiol. 2019;9:207. PubMed PMC

Marin-Acevedo J.A., Kimbrough E.O., Lou Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 2021;14(1):45. PubMed PMC

Leavy O. TIM3: dual role in immunity. Nat. Rev. Immunol. 2008;8(1) 4-4.

Carbonell R., et al. The role of biomarkers in influenza and COVID-19 community-acquired pneumonia in adults. Antibiotics. 2023;12 doi: 10.3390/antibiotics12010161. PubMed DOI PMC

Greisen S.R., Aspari M., Deleuran B. Co-inhibitory molecules - their role in health and autoimmunity; highlighted by immune related adverse events. Front. Immunol. 2022;13 PubMed PMC

Barnova M., et al. Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19. Physiol. Res. 2021;70(S2):S227–s247. PubMed PMC

Jones N.L. The tim family: new players in the Th1/Th2 paradigm. Pediatr. Res. 2002;52(1) 1-1.

Wolf Y., Anderson A.C., Kuchroo V.K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 2020;20(3):173–185. PubMed PMC

van de Weyer P.S., et al. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochemical and biophysical research communications. 2006;351(2):571–576. PubMed

Chihara N., et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558(7710):454–459. PubMed PMC

Möller-Hackbarth K., et al. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3) J. Biol. Chem. 2013;288(48):34529–34544. PubMed PMC

Hansen J.A., et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol. Blood Marrow Transplant. 2013;19(9):1323–1330. PubMed PMC

Clayton K.L., et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J. Virol. 2015;89(7):3723–3736. PubMed PMC

Polprasert C., et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Advances. 2019;3(4):588–595. PubMed PMC

Gayden T., et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat. Genet. 2018;50(12):1650–1657. PubMed

Fang H., et al. Association between TIM-3 polymorphisms and cancer risk: a meta-analysis. Ann. Transl. Med. 2019;7(20) 550-550. PubMed PMC

Razi B., et al. TIM family gene polymorphism and susceptibility to rheumatoid arthritis: systematic review and meta-analysis. PLoS One. 2019;14(2) PubMed PMC

Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010;207(10):2175–2186. PubMed PMC

Sakhdari A., et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7(7) PubMed PMC

Grabmeier-Pfistershammer K., et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade. Clin. Immunol. 2017;183:167–173. PubMed

Morou A., Palmer B.E., Kaufmann D.E. Distinctive features of CD4+ T cell dysfunction in chronic viral infections. Curr. Opin. HIV AIDS. 2014;9(5) PubMed PMC

Golden-Mason L., et al. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 2007;81(17):9249–9258. PubMed PMC

Merani S., Chen W., Elahi S. The bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections. Rev. Med. Virol. 2015;25(3):175–186. PubMed

Shi Q., et al. Negative regulation of RIG-I by tim-3 promotes H1N1 infection. Immunol. Invest. 2022:1–19. PubMed

Shahbaz S., et al. Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV. Allergy Asthma Clin. Immunol. 2023;19(1):91. PubMed PMC

Autissier P., et al. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry. 2010;77(5):410–419. PubMed

Yuan Y., et al. Peripheral blood mononuclear cell biomarkers predict response to immune checkpoint inhibitor therapy in metastatic breast cancer. Ann. Oncol. 2018;29:viii94.

Wang F., et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10) PubMed PMC

Varchetta S., et al. Unique immunological profile in patients with COVID-19. Cell. Mol. Immunol. 2021;18(3):604–612. PubMed PMC

Modabber Z., et al. TIM-3 as a potential exhaustion marker in CD4(+) T cells of COVID-19 patients. Immun Inflamm Dis. 2021;9(4):1707–1715. PubMed PMC

Shahbazi M., et al. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients. Microb. Pathog. 2021;153 PubMed PMC

Martín-Quirós A., et al. Potential role of the galectin-9/TIM-3 Axis in the disparate progression of SARS-CoV-2 in a married couple: a case report. Biomed. Hub. 2021;6(1):48–58. PubMed PMC

Yang J., et al. Increased expression of tim-3 is associated with depletion of NKT cells in SARS-CoV-2 infection. Front. Immunol. 2022;13 PubMed PMC

Coulon P.-G., et al. High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients. Front. Immunol. 2024;15 PubMed PMC

Wang F., et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10) PubMed PMC

Bobcakova A., et al. Immune profile in patients with COVID-19: lymphocytes exhaustion markers in relationship to clinical outcome. Front. Cell. Infect. Microbiol. 2021;11 PubMed PMC

Phetsouphanh C., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23(2):210–216. PubMed

Hou H., et al. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. J. Allergy Clin. Immunol. 2021;148(6):1481–1492.e2. PubMed PMC

Vazquez-Alejo E., et al. SARS-CoV2 infection during pregnancy causes persistent immune abnormalities in women without affecting the newborns. Front. Immunol. 2022;13 PubMed PMC

Wu H., et al. Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nat. Commun. 2022;13(1):269. PubMed PMC

Cazzato G., et al. HMGB1-TIM3-HO1: a new pathway of inflammation in skin of SARS-CoV-2 patients? A retrospective pilot study. Biomolecules. 2021;11(8):1219. PubMed PMC

Chen P.K., et al. Interleukin-18 is a potential biomarker to discriminate active adult-onset still's disease from COVID-19. Front. Immunol. 2021;12 PubMed PMC

Trøseid M., et al. Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: results from two Norwegian cohort studies. J. Intern. Med. 2022;292(5):816–828. PubMed PMC

Chavez-Galan L., et al. Circulating levels of PD-L1, TIM-3 and MMP-7 are promising biomarkers to differentiate COVID-19 patients that require invasive mechanical ventilation. Biomolecules. 2022;12(3):445. PubMed PMC

Kong Y., et al. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020;5(1):192. PubMed PMC

Avendaño-Ortiz J., et al. The immune checkpoints storm in COVID-19: role as severity markers at emergency department admission. Clin. Transl. Med. 2021;11(10):e573. PubMed PMC

Ueland T., et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J. Allergy Clin. Immunol. 2021;147(1):92–98. PubMed PMC

Hsieh M.C., et al. Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination. J. Chin. Med. Assoc. 2023;86(9):818–825. PubMed

Herrmann M., et al. Analysis of Co-inhibitory receptor expression in COVID-19 infection compared to acute plasmodium falciparum malaria: LAG-3 and TIM-3 correlate with T cell activation and course of disease. Front. Immunol. 2020;11:1870. PubMed PMC

Yao Y., et al. A-lactose improves the survival of septic mice by blockade of TIM-3 signaling to prevent NKT cell apoptosis and attenuate cytokine storm. Shock. 2017;47(3):337–345. PubMed

Vazquez-Alejo E., et al. SARS-CoV2 infection during pregnancy causes persistent immune abnormalities in women without affecting the newborns. Front. Immunol. 2022;13 PubMed PMC

Chen R., et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. 2020;6(12) PubMed PMC

Avery L., et al. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc. Natl. Acad. Sci. USA. 2018;115(10):2455–2460. PubMed PMC

Smith C.M., et al. Phosphatidylserine binding directly regulates TIM-3 function. Biochem. J. 2021;478(17):3331–3349. PubMed PMC

Lee J., et al. TIM polymorphisms--genetics and function. Genes Immun. 2011;12(8):595–604. PubMed PMC

Murtaza A., et al. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. European Journal of Cancer. 2016;69

Saresella M., et al. A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. Faseb j. 2014;28(11):5000–5009. PubMed

Zhu C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005;6(12):1245–1252. PubMed

Dapat I.C., et al. Secretion of galectin-9 as a DAMP during dengue virus infection in THP-1 cells. Int. J. Mol. Sci. 2017;18(8) PubMed PMC

Bozorgmehr N., et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio. 2021;12(3) PubMed PMC

Du L., et al. Human galectin-9 potently enhances SARS-CoV-2 replication and inflammation in airway epithelial cells. J. Mol. Cell Biol. 2023;15(4):mjad030. doi: 10.1093/jmcb/mjad030. PubMed DOI PMC

DeKruyff R.H., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 2010;184(4):1918–1930. PubMed PMC

Zhao D., et al. Frontline Science: tim-3-mediated dysfunctional engulfment of apoptotic cells in SLE. J. Leukoc. Biol. 2017;102(6):1313–1322. PubMed

Nakayama M., et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113(16):3821–3830. PubMed

Tan S., et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling. Cancer Res. 2020;80(5):1130–1142. PubMed

Althaus K., et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061–1071. PubMed PMC

Curtin J.F., et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1) PubMed PMC

Tesniere A., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–491. PubMed

de Mingo Pulido A., et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54(6):1154–1167. e7. PubMed PMC

Wyganowska-Swiatkowska M., et al. Influence of herbal medicines on HMGB1 release, SARS-CoV-2 viral attachment, acute respiratory failure, and sepsis. A literature review. Int. J. Mol. Sci. 2020;21 doi: 10.3390/ijms21134639. PubMed DOI PMC

Zou H., et al. Destruction in maternal-fetal interface of URSA patients via the increase of the HMGB1-RAGE/TLR2/TLR4-NF-κB signaling pathway. Life Sci. 2020;250 PubMed

Chen L., et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell. Mol. Immunol. 2020;17(9):992–994. PubMed PMC

Chen G., et al. Pathogenic role of HMGB1 in SARS? Med. Hypotheses. 2004;63(4):691–695. PubMed PMC

Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 2006;6(6):433–446. PubMed

Huang Y.H., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–390. PubMed PMC

Khairnar V., et al. CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. Nat. Commun. 2018;9(1):2561. PubMed PMC

Sabatos-Peyton C.A., et al. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology. 2018;7(2) PubMed PMC

Klaile E., et al. Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respir. Res. 2013;14(1):85. PubMed PMC

Liao M., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. PubMed

Huang R., et al. The predicting roles of carcinoembryonic antigen and its underlying mechanism in the progression of coronavirus disease 2019. Crit. Care. 2021;25(1):234. PubMed PMC

Saheb Sharif-Askari N., et al. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. Molecular Therapy - Methods & Clinical Development. 2021;20:109–121. PubMed PMC

Bohan D., et al. Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathog. 2021;17(11) PubMed PMC

Ferris R.L., Lu B., Kane L.P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J. Immunol. 2014;193(4):1525–1530. PubMed PMC

Yuan C., et al. The role of cell death in SARS-CoV-2 infection. Signal Transduct. Targeted Ther. 2023;8(1):357. PubMed PMC

Alrajhi N.N. Post-COVID-19 pulmonary fibrosis: an ongoing concern. Ann. Thorac. Med. 2023;18(4):173–181. PubMed PMC

Hotchkiss R.S., et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45(10):1360–1371. PubMed PMC

Lee L.Y., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. PubMed PMC

Yang K., et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–913. PubMed PMC

Mehta V., et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system. Cancer Discov. 2020;10(7):935–941. PubMed PMC

Robilotti E.V., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 2020;26(8):1218–1223. PubMed PMC

He Y., et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets Ther. 2018;11:7005–7009. PubMed PMC

Luo J., et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10(8):1121–1128. PubMed PMC